Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy
Küçük Resim Yok
Tarih
2017
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
ELSEVIER
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Aim: We aimed to evaluate impact of spironolactone (S) on cardiovascular toxicity of concomitant use of radiotherapy (RT) and trastuzumab (T). Background: S, an aldosterone receptor antagonist, is known to ameliorate the cardiac damage. S ameliorates anthracycline-induced cardiotoxicity, there is no data regarding to effect of S on both T and radiation-induced cardiotoxicity. Materials/Methods: Eighty rats were divided into eight groups: group (G) 1 was defined as control group. G2, G3 and G4 were RT, S and T groups respectively. G5, G6, G7 and G8 were RT + T, T + S, RT + S and RT + T + S groups respectively. Rats were sacrificed at 6th hour; 21st and 100th days after RT. Heart and thoracic aorta samples were taken for microscopical examination. Results: Cardiac inflammation and fibrosis scores and; TGF-8 expression were not significantly different within study groups at 6th hour and 21st days of RT. By 100th days of RT fibrosis scores and TGF-expression in cardiac samples were significantly different between study groups (p values were 0.004 and 0.002 respectively). Pair-wise comparisons revealed that both cardiac fibrosis scores and TGF-8 expression levels were higher in G5 when compared to G8 (p values were 0.046 and 0.028 respectively). Moreover the TGF-8 expression was higher in G5 when compared to G2 (p =0.046). We could not demonstrate any significant differences with respect to inflammation, fibrosis and TGF-8 expression in thoracic aorta samples between study groups. Conclusions: Although S had a protective effect on cardiac tissue it had no protective effect on thoracic aorta when administered with RT + T. (C) 2017 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
Açıklama
Anahtar Kelimeler
Aldosterone, Cardiovascular toxicity, Radiotherapy, Spironolactone, Trastuzumab
Kaynak
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY
WoS Q Değeri
N/A
Scopus Q Değeri
Q3
Cilt
22
Sayı
4
